FOR FURTHER INFORMATION CONTACT: Theresa Kingsberry (phone: 202–326–3100), Program Support Specialist, Federal Trade Commission, Bureau of Competition, Premerger Notification Office, Washington, DC 20024.

By direction of the Commission.

April J. Tabor,

Secretary.

[FR Doc. 2026–07322 Filed 4–14–26; 8:45 am]

BILLING CODE 6750–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Tribal Consultation Meeting

AGENCY: Office of Head Start (OHS), Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: Pursuant to the Head Start Act, notice is hereby given of one Tribal Consultation session to be held between HHS/ACF OHS leadership and the leadership of tribal governments operating Head Start and Early Head Start programs. The purpose of this consultation session is to discuss ways to better meet the needs of American Indian and Alaska Native (AIAN) children and their families, taking into consideration funding allocations, distribution formulas, and other issues affecting the delivery of Head Start services in their geographic locations.

DATES: Thursday, June 18, 2026, 8:30 a.m.–11:00 a.m. PT.

ADDRESSES: June 18, 2026, 8:30 a.m. to 11:00 a.m. PT, (Hilton Orange County/Costa Mesa, 3050 Bristol Street, Costa Mesa, CA 92626).

FOR FURTHER INFORMATION CONTACT: Office of Head Start, email *AIANHeadStart@acf.hhs.gov.* Additional information and online meeting registration will be forthcoming.

SUPPLEMENTARY INFORMATION: In accordance with section 640(l)(4) of the Head Start Act, 42 U.S.C. 9835(1)(4), ACF announces OHS Tribal Consultation session for leaders of tribal governments operating Head Start and Early Head Start programs.

The agenda for the scheduled OHS Tribal Consultation reflects the statutory purposes of Head Start Tribal Consultations related to meeting the needs of AIAN children and families. OHS will also highlight the progress made in addressing issues and concerns raised in the previous OHS Tribal Consultations.

The consultation session includes elected or appointed leaders of tribal governments and their designated representatives. Designees must have a letter from the tribal government authorizing them to represent the tribe. Tribal governments must submit the designee letter at least 3 days before the consultation sessions to OHS at *AIANHeadStart@acf.hhs.gov.* Other representatives of tribal organizations and Native nonprofit organizations are welcome to attend as observers.

Within 45 days of the consultation session, a detailed report of the consultation session will be available for all tribal governments receiving funds for Head Start and Early Head Start programs. Tribes can submit written testimony for the report to the OHS at *AIANHeadStart@acf.hhs.gov* prior to the consultation session or within 30 days of each meeting. OHS will summarize oral testimony and comments from the consultation session in the report, along with topics of concern and recommendations.

Roshelle M. Brooks,

Management Analyst and OFR Liaison.

[FR Doc. 2026–07318 Filed 4–14–26; 8:45 am]

BILLING CODE 4184–40–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2025–N–4731]

Increasing Access to Nonprescription Drugs; Public Meeting; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting; request for comments.

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is announcing a public meeting entitled ''Increasing Access to Nonprescription Drugs.'' The purpose of the public meeting is to discuss perspectives from interested parties on increasing access to nonprescription drugs. We are also requesting comments.

DATES: The public meeting will be held virtually and in person on April 23, 2026, from 12:30 p.m. to 5 p.m. Eastern Time. Either electronic or written comments on this public meeting must be submitted by May 8, 2026. See the **SUPPLEMENTARY INFORMATION** section for registration date and information.

ADDRESSES: The public meeting will be held virtually using the Zoom platform and in person at the National Press Club, 529 14th Street NW, Washington, DC 20045, with limited seat availability.

You may submit comments as follows. Please note that late, untimely filed comments will not be considered. The *https://www.regulations.gov* electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of May 8, 2026. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov.*
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include the Docket No. FDA–2025–N–4731 for ''Increasing